FTC Accuses CVS, Cigna, And UnitedHealth Of Marking Up Cancer, HIV Drugs

Jan 16, 2025

ID 72420048 © Typhoonski | Dreamstime.com — © Typhoonski | Dreamstime.com

Three major drug middlemen needlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 billion in revenue, The Federal Trade Commission (FTC) said in a report released today.

[Continue reading below]

CVS will cut almost 3,000 jobs as it plans AI investments — and considers breaking up

The findings were revealed in the agency’s second interim staff report on the prescription drug middleman industry.

In theory, PBMs are meant to be third-party companies that are middlemen between drugmakers and insurance providers. But the FTC said last year this proves problematic because PBMs are “vertically integrated” with both large health insurers and specialty and retail pharmacies.

The results have created a system where “leading PBMs now exercise significant power over Americans’ ability to access and afford their prescription drugs,” the FTC said.

In their second report, the FTC outlined how this came at the expense of consumers, who were left with no option but to spend on marked-up drugs that should have cost less. In some cases, the FTC said that drugs dispensed at the companies affiliated pharmacies were marked up “hundreds and thousands of percent.” The FTC reported that a disproportionate share of specialty drugs marked up more than $1,000 per prescription were done so by PBMs operated by CVS, Cigna, and UnitedHealth, compared to unaffiliated pharmacies. The agency also suggested that the three companies “may be steering highly profitable prescriptions to their own affiliated pharmacies.”

FTC Chair Lina Kahn said in a statement Tuesday it is clear these three PBMs “hiked costs for a wide range of lifesaving drugs, including medications to treat heart disease and cancer.”

Kahn, who is set to leave the FTC when President-elect Donald Trump takes office, said she believes “the FTC should keep using its tools to investigate practices that may inflate drug costs, squeeze independent pharmacies, and deprive Americans of affordable, accessible healthcare—and should act swiftly to stop any illegal conduct.”

Trump has nominated Federal Trade Commissioner Andrew Ferguson to lead the department.

Disclaimer

The information contained in South Florida Reporter is for general information purposes only.
The South Florida Reporter assumes no responsibility for errors or omissions in the contents of the Service.
In no event shall the South Florida Reporter be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service. The Company reserves the right to make additions, deletions, or modifications to the contents of the Service at any time without prior notice.
The Company does not warrant that the Service is free of viruses or other harmful components

This article originally appeared here and was republished with permission.